Government prescription drug pricing policy and the interplay with investment in life sciences

A webinar presented by the IBA Healthcare and Life Sciences Law Committee

New prescription drugs and biologics have the potential to help patients around the world. In this webinar, the speakers will each share a brief overview of key attributes and updates relating to their region’s approach to the pricing of medicine.

The speakers will consider how updated government policies are impacting:

• the direction of scientific research; and
• investment by private and public entities.

This topic is important no matter where a company is located. We are now witnessing the seismic impact of new strategies by governments to reign in prices for prescription drugs and biologics.

Join the panel for this timely discussion about how policies around the world are transforming how the life sciences industry values products and assesses which products warrant continued research and development.

Not only does this topic directly impact our clients, but it also directly affects each and every one of us. The policies in effect today will have a long-lasting impact on which medical conditions will be prioritised for research and ultimately whether there will be effective treatments to treat illness and cure disease.